Drug development

Identification Of Compound – Drug Development:

In this 21st century the human beings are effected by various types of diseases, therefore the development of new drug candidates is in high priority. Research work done by Walter and Eliza Hall Institute’s medicinal chemistry group helped in reaching this priority and also helped in simplifying the identification of compound that can be promising candidate for drug development.

Thanks to Dr Jonathan Baell and Dr Georgina Holloway for developing a series of “filter” which can comb out those molecules which generate fake positives while screening a chemical library for compounds that could be useful in drug development.

By the help of High-throughput chemical screening (HTCS) we can actively identify a chemical compounds that are capable of interacting with target protein and are therefore regarded as a potential compound for drug development. It is expected that there are 30,000 to one million compounds present in a screening library and thousands of compounds may be taken as ‘positive’ for interaction with a protein of choice. These compounds are then taken as a subject of time consuming medicinal chemistry as scientist seeks to refine them for entry into the drug development pipeline.

According to Dr Baell, about 10 % of compounds in any commercially available screening library show false positives, wasting productive time of scientists’ as they undertake labor-intensive medicinal chemistry to optimize these molecules.

Dr Baell said, they are planing to remove those molecules from screening process which trick scientists to think that they could be useful for being developed into drug to treat disease but instead become dead end.

Dr Baell has also taken the initiative to simplify the identification of these troublesome molecules by creating ‘filters’, text files that can be incorporate into the software to screen the available chemical libraries. These filters were made publically available on 4th February through online publication in the Journal of Medicinal Chemistry.

Large pharmaceutical companies employ High-throughput chemical screening for more than 20 years. In the past, scientists at universities and research institutes and in small biotechnology companies have had increasing access to HTCS. As per Dr Baell, they were having all data, software as well as expertise to identify these molecules. More importantly, they were also having the capability and ability to publish their data.

He shared that pharmaceutical companies have used high-throughput chemical screening for many years and that’s how they are aware of those compounds that turn up as false positives. These pharma companies also operate in a competitive environment where publishing this date could be compromising their competitive edge. But for this specific situation they were not having any constraints.

Dr Baell also added that just after 48 hrs from the time of publishing about the filters, he started receiving queries from number of pharmaceutical companies interested in using them to access their impact on their own high throughput libraries.

For more updates visit HarNeedi.com OR Follow us at Facebook, LinkedIn and Twitter.